Hindustan Biosciences Limited is engaged in the manufacturing and sale of pharmaceutical products.Product Portfolio: a) Tablets b) Capsules c) Eye/Ear/Nasal Drops d) Dry and Liquid Injectables e) Liquid/Dry Syrups f) Pre-Filled Syringes g) Non Sterile/Sterile Ointments
Hindustan Bio Sciences will hold its 34th Annual General Meeting on September 30 at its registered office. The company has informed shareholders about the AGM, e-voting procedures, and book closure. E-voting will be available from September 27 to September 29. Shareholders eligible to vote will be determined as of September...
With Reference to the subject cited please find the 34th Annual Report along with the intimation for the financial year 2025-26
Hindustan Biosciences' board approved a capital reduction scheme. This will cancel 56.38 lakh shares of ₹2 each (pro-rata), reducing paid-up capital from ₹2.05 Cr to ₹0.92 Cr and setting off ₹1.13 Cr in accumulated losses. Shares will also consolidate to ₹10 face value.
Hindustan Bio Sciences has announced a board meeting on Aug 31st. The agenda includes considering a draft share capital restructuring plan. The trading window closes Aug 27 until 48 hours post-meeting.
Hindustan Biosciences has announced the publication of its financial results for the quarter ended June 30, 2026. The company reported zero revenue from operations and incurred total expenses of 0.11 Cr, leading to a net loss of 0.11 Cr for the period. The Board of Directors approved these unaudited results,...
